FDA Approves Luye Pharma’s Bi-Weekly Extended-Release Risperidone For Schizophrenia & Bipolar I

Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the research and development (R&D), manufacturing, and sale of innovative medications, announced that the U.S. Food and Drug Administration (FDA) has approved Rykindo® (risperidone) for extended-release injectable suspension for the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. Rykindo® is administered via intramuscular injection once every two weeks and delivers its active ingredient, risperidone, via long-acting and extended-release microsphere technology.

Rykindo® was developed by Luye . . .